A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 35, 2013, Pages 5910-5916

  He, Yi Fu ^a   Ji, Chu Shu ^a   Hu, Bing ^a   Fan, Ping Sheng ^b   Hu, Chang Lu ^a   Jiang, Feng Shou ^a   Chen, Jian ^a   Zhu, Lei ^b   Yao, Yi Wei ^a   Wang, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL CANCER HOSPITAL   (China)

Author keywords

Esophageal squamous cell cancer; Frontline chemotherapy; Nedaplatin; Paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; NEDAPLATIN; PACLITAXEL; PROMETHAZINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHINESE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS METASTASIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ESOPHAGEAL SQUAMOUS CELL CANCER; FRONT-LINE CHEMOTHERAPY; NEDAPLATIN; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885582190     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i35.5910     Document Type: Article

References (34)

1. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236: 376-384; discussion 384-385 [PMID: 12192324 DOI: 10.1097/00000658-200209000-00014]
2. Vestermark LW, Sørensen P, Pfeiffer P. [Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review]. Ugeskr Laeger 2008; 170: 633-636 [PMID: 18364154]
3. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 2003; 29: 525-532 [PMID: 14585262 DOI: 10.1016/S0305-7372(03)00104-X]
4. Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H, Jin Y. A phase II study of paclitaxel and nedaplatin as firstline chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol 2009; 39: 582-587 [PMID: 19509000 DOI: 10.1093/jjco/hyp058]
5. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol 2009; 64: 327-333 [PMID: 19048253 DOI: 10.1007/s00280-008-0874-8]
6. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-1220 [PMID: 9301445 DOI: 10.1016/S0959-8049(97)00088-9]
7. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-1091 [PMID: 7912736 DOI: 10.1093/jnci/86.14.1086]
8. Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 2005; 20: 618-623 [PMID: 16100454 DOI: 10.3346/jkms.2005.20.4.618]
9. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004; 15: 960-965 [PMID: 15151955 DOI: 10.1093/annonc/mdh230]
10. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007; 18: 898-902 [PMID: 17351256 DOI: 10.1093/annonc/mdm004]
11. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002; 86: 669-673 [PMID: 11875723 DOI: 10.1038/ sj.bjc.6600166]
12. Zhang X, Shen L, Li J, Li Y, Li J, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 2008; 31: 29-33 [PMID: 18376224 DOI: 10.1097/COC.0b013e3181131ca9]
13. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990; 52: 15-24 [PMID: 2356567 DOI: 10.1016/03 78-4274(90)90161-E]
14. Kobayashi H, Takemura Y, Miyachi H, Ogawa T. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Invest New Drugs 1991; 9: 313-319 [PMID: 1804804 DOI: 10.1007/BF00183571]
15. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005; 28: 1385-1388 [PMID: 16079479 DOI: 10.1248/bpb.28.1385]
16. Alberts DS, Fanta PT, Running KL, Adair LP, Garcia DJ, Liu-Stevens R, Salmon SE. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 1997; 39: 493-497 [PMID: 9118460 DOI: 10.1007/s002800050604]
17. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004; 40: 1000-1006 [PMID: 15509491]
18. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho 1992; 19: 483-488 [PMID: 1558398]
19. Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, Nakagawa K, Fukuoka M. Combination phase I study of nedaplatin and gemcitabine for advanced nonsmall-cell lung cancer. Br J Cancer 2004; 90: 2092-2096 [PMID: 15150564 DOI: 10.1038/sj.bjc.6601817]
20. Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Shirai T, Ohnishi T, Horichi N, Ohmori T, Adachi M. Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2008; 61: 829-835 [PMID: 17589845 DOI: 10.1007/s00280-007-0540-6]
21. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus]. Gan To Kagaku Ryoho 1992; 19: 885-892 [PMID: 1605666]
22. Sekine I, Nokihara H, Horiike A, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Br J Cancer 2004; 90: 1125-1128 [PMID: 15026789 DOI: 10.1038/sj.bjc.6601700]
23. Tanaka R, Takii Y, Shibata Y, Ariyama H, Qin B, Baba E, Kusaba H, Mitsugi K, Harada M, Nakano S. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol 2005; 56: 279-285 [PMID: 15875187 DOI: 10.1007/s00280-004-0991-y]
24. Yamada H, Uchida N, Maekawa R, Yoshioka T. Sequencedependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 2001; 172: 17-25 [PMID: 11595125 DOI: 10.1016/S0304-3835(01)00614-0]
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10 [PMID: 2702835 DOI: 10.1016/0197-2456(89)90015-9]
26. Bai SX. Primary esophageal adenocarcinoma--report of 19 cases. Zhonghua Zhongliu Zazhi 1989; 11: 383-385 [PMID: 2620638]
27. Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2005
28. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008; 62: 77-84 [PMID: 17762932 DOI: 10.1007/s00280-007-0577-6]
29. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16: 1826-1834 [PMID: 9586897]
30. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-3275 [PMID: 10506629]
31. Kanai M, Matsumoto S, Nishimura T, Shimada Y, Watanabe G, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Teramukai S, Mitsumori M, Chiba T, Sakai Y, Fukushima M. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol 2007; 12: 224-227 [PMID: 17566847 DOI: 10.1007/s10147-007-0666-x]
32. Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, Philips H, Price A, Dunlop D, Eatock M. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 2005; 93: 1112-1116 [PMID: 16278660 DOI: 10.1038/sj.bjc.6602842]
33. Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 2004; 22: 91-97 [PMID: 14707499]
34. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46 [PMID: 18172173 DOI: 10.1056/NEJMoa073149]